




Evaluierung der Rolle von 13-cis-Retinsäure bei einer Langzeitinfusion des anti-GD2 Antikörpers Dinutuximab beta in der post-Konsolidierungstherapie des Hochrisiko-Neuroblastoms

HINTERGRUND

Therapie des Hochrisiko-Neuroblastoms



METHODEN



ERGEBNISSE


Wachstum

GD2-Expression


mit PBMCs

mit PBMCs + DB


COG-N-440-NIR680
noradrenerg GD2 +



LAN-1-NIR680
Intermediär GD2 +




CHLA-90-NIR680
mesenchymal GD2 -



idem

idem



idem